Delivery Order SPE2DB24D3013-SPE2DB26FFGAT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,418.56 to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30s, with an ultimate completion date of July 18, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Lidocaine 5% Patch 30-count units, with a ceiling value of $10,834.22 and firm fixed pricing. This competitively awarded, non-set-aside delivery order is scheduled for completion by June 17, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's substantial...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,596.64 to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30S, with an ultimate completion date of November 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively on October 31, 2025. The place of performance is listed as the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30s under a firm fixed-price contract valued at $2,421.44, with an ultimate completion date of August 8, 2025. This competitively awarded, non-set-aside delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor for federal medical procurement. The work will be performed at the company's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,866.60 to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30s, with an ultimate completion date of April 29, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,772.64 to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30s, with an ultimate completion date of September 17, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Lidocaine 5% Patch 30s, with a ceiling value of $5,418.73. This firm fixed-price delivery order, with an ultimate completion date of September 15, 2025, represents a competitive award with no set-aside designation. The order will be performed at the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,722.08 to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Lidocaine 5% Patch 30s, with completion scheduled for September 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $2,644.06 to AmerisourceBergen Drug Corp for the procurement of Lidocaine 5% Patch 30s, with an ultimate completion date of September 12, 2025. This competitive, firm fixed-price delivery order was issued on September 11, 2025, with no set-aside designation. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $9,331.75 to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30s, with an ultimate completion date of September 16, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFGATDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,357.45 to AmerisourceBergen Drug Corp for the supply of Lidocaine 5% Patch 30s, with an ultimate completion date of November 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a critical pharmaceutical distributor for federal medical procurement. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and other federal customers, including the Defense Health Agency and U.S. Coast Guard. The company's extensive federal contracting history demonstrates its established capability to meet DLA requirements across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.4k | 10/31/25 |